Testing requirements are likely slowing biosimilar entries in the US

Biosimilars have been slow to enter the US market for complex reasons ranging from the manipulation of patent protections to brand-name drug rebates. Now a new analysis, published in the Mayo Clinic Proceedings, suggests that a “high testing bar” for biosimilars to gain regulatory approval is another contributing factor.